22:28:26 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-27 Kvartalsrapport 2024-Q2
2024-05-24 Kvartalsrapport 2024-Q1
2024-04-26 Ordinarie utdelning DBP B 0.00 SEK
2024-04-25 Årsstämma 2024
2024-02-27 Bokslutskommuniké 2023
2023-11-14 Kvartalsrapport 2023-Q3
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-05-19 Ordinarie utdelning DBP B 0.00 SEK
2023-05-17 Årsstämma 2023
2023-02-24 Bokslutskommuniké 2022
2022-11-14 Kvartalsrapport 2022-Q3
2022-08-27 Kvartalsrapport 2022-Q2
2022-05-27 Kvartalsrapport 2022-Q1
2022-04-11 Extra Bolagsstämma 2022
2022-04-08 Ordinarie utdelning DBP B 0.00 SEK
2022-04-07 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-12 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-04-21 Kvartalsrapport 2021-Q1
2021-04-21 Årsstämma 2021
2021-04-08 Ordinarie utdelning DBP B 0.00 SEK
2021-02-25 Bokslutskommuniké 2020
2020-11-23 Kvartalsrapport 2020-Q3
2020-09-07 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-06-12 Ordinarie utdelning DBP B 0.00 SEK
2020-06-11 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-21 Bokslutskommuniké 2019
2019-11-25 Kvartalsrapport 2019-Q3
2019-08-27 Kvartalsrapport 2019-Q2
2019-05-07 Kvartalsrapport 2019-Q1
2019-04-09 Ordinarie utdelning DBP B 0.00 SEK
2019-04-08 Årsstämma 2019
2018-11-13 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2018-05-07 Kvartalsrapport 2018-Q1
2018-04-10 Ordinarie utdelning DBP B 0.00 SEK
2018-04-09 Årsstämma 2018
2018-02-23 Bokslutskommuniké 2017
2017-08-25 Kvartalsrapport 2017-Q2
2017-05-09 Ordinarie utdelning DBP B 0.00 SEK
2017-05-08 Årsstämma 2017
2017-05-05 Kvartalsrapport 2017-Q1
2017-02-20 Bokslutskommuniké 2016
2016-11-11 Kvartalsrapport 2016-Q3
2016-08-26 Kvartalsrapport 2016-Q2
2016-05-10 Ordinarie utdelning DBP B 0.00 SEK
2016-05-09 Årsstämma 2016
2016-05-04 Kvartalsrapport 2016-Q1
2016-02-19 Bokslutskommuniké 2015
2015-10-23 Kvartalsrapport 2015-Q3
2015-08-14 Kvartalsrapport 2015-Q2

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriBioteknik
Double Bond Pharmaceutical, DBP, är ett läkemedelsbolag. Störst affärsinriktning innehas mot behandling av cancersjukdomar, infektioner och autoimmuna sjukdomar. Forskningen utgår ifrån bolagets egenutvecklade drug-delivery teknologi. Produkterna säljs under separata varumärken och samarbeten vid produktutveckling sker med andra aktörer inom branschen. Bolaget har sitt huvudkontor i Uppsala.
2023-02-08 07:48:55

Double Bond Pharmaceutical International AB (publ) ("DBP") notes the announcement released earlier yesterday by Hemcheck Sweden AB  ("Hemcheck") and is pleased to announce that its 20% owned investee company Bio Vitos has today entered into an agreement with Hemcheck, a company listed on the Nasdaq Stockholm (the "Agreement").  As part of the Agreement Hemcheck will create a new subsidiary ("NewCo") and transfer all current business and assets of Hemcheck to this new subsidiary. Under the terms of the Agreement, Bio Vitos has agreed to provide the NewCo with  SEK1.23 million in cash, plus any applicable VAT, on signing of the Agreement,  within 14 days after the distribution of the shares in NewCo to Hemcheck's shareholders.

Bio Vitos will then pay a further SEK4 million in cash, plus any applicable VAT, to Hemcheck, within thirty days following the distribution of shares in NewCo to Hemcheck Sweden AB shareholders. 

In addition Bio Vitos has agreed to provide Hemcheck with its IP rights (patents or patent applications) in respect of  an active substance Iron Succinate (Succifer and used in a marketed product Inofer). In exchange, Bio Vitos will receive 259,654,000 shares in Hemcheck, amounting to circa 88.3% of Hemcheck's share capital.

DBP's holding in Bio Vitos will remain unchanged.

The Board  of DBP is informed by Bio Vitos that under the rules of the Nasdaq Stockholm this is deemed to constitute a reverse takeover for Hemcheck. It is anticipated that subject to all required shareholder and regulatory approvals, that Hemcheck will remain listed on the Nasdaq Stockholm.

The full text of the announcement released by Hemcheck yesterday:

https://mb.cision.com/Main/16884/3710632/1832822.pdf

More about DBP's position in Bio Vitos: https://mb.cision.com/Main/12720/3455944/1498083.pdf

This disclosure contains information that DBP is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 08-02-2023 07:48 CET.